Relationship between KS tumor response and change in CD4 count
. | . | Response, no. (%) . | . | . | ||
|---|---|---|---|---|---|---|
| Response vs entry: change in CD4 count, cells/mm3 . | No. of evaluable patients . | Partial response . | Stable disease . | Progressive disease . | ||
| Within 50 of entry | 6 | 1 (17) | 0 (0) | 5 (83) | ||
| Decrease by more than 50 | 16 | 12 (75) | 1 (6) | 3 (19) | ||
| Increase by more than 50 | 6 | 4 (67) | 2 (33) | 0 (0) | ||
| Increase by more than 100 | 3 | 3 (67) | 1 (33) | 0 (0) | ||
. | . | Response, no. (%) . | . | . | ||
|---|---|---|---|---|---|---|
| Response vs entry: change in CD4 count, cells/mm3 . | No. of evaluable patients . | Partial response . | Stable disease . | Progressive disease . | ||
| Within 50 of entry | 6 | 1 (17) | 0 (0) | 5 (83) | ||
| Decrease by more than 50 | 16 | 12 (75) | 1 (6) | 3 (19) | ||
| Increase by more than 50 | 6 | 4 (67) | 2 (33) | 0 (0) | ||
| Increase by more than 100 | 3 | 3 (67) | 1 (33) | 0 (0) | ||
Depicted are patients who received 300 ng/kg or more IL-12 and were evaluable for tumor response. Change in CD4 cell count is calculated from the time of entry until the time that patients achieved a tumor response (partial response, progressive disease, or stable disease). Patients with stable disease are assessed at the time they left the study. Patients who went on to develop a complete response are assessed at the time of their first partial response.